Engineered immune cells take on Hard-to-Treat cancers in early trial
Disease control
Ongoing
This early-stage trial tests a personalized cell therapy for people with advanced colorectal, pancreatic, or lung cancers that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune T cells, engineering them to recognize and attack cancer cells, …
Phase: PHASE1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC